Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain

por Darbà, Josep, Kaskens, Lisette, Sorio Vilela, Francesc, Lothgren, Mickael
Publicado 2015

Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline

por Journath, Gunilla, Hambraeus, Kristina, Hagström, Emil, Pettersson, Billie, Löthgren, Mickael
Publicado 2017

Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection

por Asseburg, Christian, Willis, Michael, Löthgren, Mickael, Seppälä, Niko, Hakala, Mika, Persson, Ulf
Publicado 2012

Cost‐Effectiveness of LDL‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States

por Gandra, Shravanthi R., Villa, Guillermo, Fonarow, Gregg C., Lothgren, Mickael, Lindgren, Peter, Somaratne, Ransi, van Hout, Ben
Publicado 2016

Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain

por Quilici, Sibilia, Chancellor, Jeremy, Löthgren, Mickael, Simon, Dominique, Said, Gérard, Le, Trong Kim, Garcia-Cebrian, Ana, Monz, Brigitta
Publicado 2009

Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related...

por Lothgren, Mickael, Ribnicsek, Erna, Schmidt, Louise, Habacher, Wolfgang, Lundkvist, Jonas, Pfeil, Alena M, Biteeva, Irina, Vrouchou, Polina, Bracco, Andrea
Publicado 2013

Acute and chronic impact of cardiovascular events on health state utilities

por Matza, Louis S, Stewart, Katie D, Gandra, Shravanthi R, Delio, Philip R, Fenster, Brett E, Davies, Evan W, Jordan, Jessica B, Lothgren, Mickael, Feeny, David H
Publicado 2015